Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Does the Projected Growth of the Short-Acting Insulin Market Compare Over the Forecast Period?

In the past few years, the short-acting insulin market has experienced robust growth. The size of the market is set to expand from $11.00 billion in 2024 to $11.65 billion in 2025, marking a compound annual growth rate (CAGR) of 5.9%. The soaring growth during the historic period can be traced back to factors such as a hike in the number of type 1 diabetes patients, a surging aged population, increased funds for research and development, the frequency of diagnosed cases, and a rise in urbanization.

In the next few years, the market size of short-acting insulin is projected to undergo significant growth, expanding to $14.47 billion in 2029 with a compound annual growth rate (CAGR) of 5.6%. This predicted growth during the forecast period can be attributed to factors such as heightened governmental initiatives, increased support from authorities, swift advancements in production procedures, rising prevalence of insulin therapy adoption, and the emergence of personalized medicine. The forecast period is also expected to witness certain trends in the form of advancements in insulin delivery mechanisms and technology, the creation of innovative fast-acting insulin analogs, the emergence of biosimilars, a shift towards prioritizing patient-focused care, and advancements in insulin formulation methods.

Which Primary Drivers Are Supporting the Continued Expansion of the Short-Acting Insulin Market?

The escalating incidences of type 1 diabetes are anticipated to stimulate the expansion of the short-acting insulin market in the future. Type 1 diabetes, an autoimmune disorder where the body eradicates cells that produce insulin, necessitates a lifetime requirement for insulin therapy. The augmented incidences of Type 1 diabetes are propelled by genetic elements, environmental instigators, and a rise in autoimmune conditions. By offering swift glucose control and imitating the natural insulin reaction, short-acting insulin plays a key role in managing type 1 diabetes. For example, Diabetes Australia, an organization based in Australia advocating diabetes awareness, stated that around 134,000 Australians were dealing with Type 1 diabetes in 2022. By 2023, this number had risen to 135,423. Consequently, the escalating incidences of type 1 diabetes are propelling the expansion of the short-acting insulin market.

Explore Comprehensive Insights Into The Global Short-Acting Insulin Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Who Are the Key Players Steering the Development of the Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., Adocia S.A.S.

How Are Consumer Trends Shaping the Current and Future Landscape of the Short-Acting Insulin Market?

Key players in the short-acting insulin market are prioritizing the development of innovative items like insulin pods. These pods are tubeless, wearable insulin dispersion systems aiming to provide continuous insulin delivery for diabetes patients. For instance, the U.S. medical device firm, Insulet Corporation, announced in April 2023 that the U.S. Food and Drug Administration (FDA) had cleared the Omnipod GO. This is an innovative, basal-only insulin pod tailored to adult individuals suffering from type 2 diabetes. The device, which is tubeless and wearable, provides a constant insulin supply without requiring a separate controller. The Omnipod GO revolutionizes diabetes management by eradicating the need for daily injections and offering pre-set insulin rates. Its appealing design and pharmacy availability enhances convenience for patients and healthcare providers alike. This product launch confirms Insulet’s dedication to enhance diabetes treatment through creative technology.

Secure Your Global Short-Acting Insulin Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

Which Primary Segments of the Short-Acting Insulin Market Are Driving Growth and Industry Transformations?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

Which Geographical Regions Are Shaping the Short-Acting Insulin Market Growth?

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Aspects of the Short-Acting Insulin Market Landscape?

Short-acting insulin is a type of insulin that is used to control blood sugar levels during or after meals. It begins to work within 30 minutes to 1 hour, peaks at around 2-3 hours, and has a duration of action of 4-6 hours. Short-acting insulin plays a vital role in regulating blood glucose by facilitating the uptake of glucose into cells, which the body then uses for energy, particularly after the consumption of food.

Browse Through More Similar Reports By The Business Research Company:

Venous Thromboembolism Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

Thrombophilia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Deep Vein Thrombosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/deep-vein-thrombosis-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: